Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the t... Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Mehr anzeigen
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to...
Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% Received Approval for Estyme® Injectable Hyaluronic Acid (HA) Gels in the European Union;...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification...
Achieves 2 Million Jeuveau® Redemptions Anticipates Launch of Club Evolus™, the first consumer membership program by a neurotoxin manufacturer, on November 4, 2024 Evolus, Inc. (NASDAQ: EOLS), a...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.68 | -5.87726879862 | 11.57 | 11.83 | 10.64 | 582207 | 11.29006954 | CS |
| 4 | -2.23 | -16.9969512195 | 13.12 | 14.33 | 10.64 | 530601 | 12.35595266 | CS |
| 12 | -5.54 | -33.7188070603 | 16.43 | 17.82 | 10.64 | 603465 | 14.35174713 | CS |
| 26 | 0.31 | 2.93005671078 | 10.58 | 17.82 | 10.24 | 561048 | 14.2060754 | CS |
| 52 | 0.75 | 7.39644970414 | 10.14 | 17.82 | 9.65 | 577267 | 13.48800386 | CS |
| 156 | 4.81 | 79.1118421053 | 6.08 | 17.82 | 5.061 | 546739 | 10.7517717 | CS |
| 260 | -1.61 | -12.88 | 12.5 | 17.82 | 2.85 | 646805 | 9.34769605 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
